Meeting
2018 ASCO Annual Meeting
Economic evaluation for the US of venetoclax (VEN) versus ibrutinib (IBR) versus allogeneic hematopoietic stem-cell transplantation (HSCT) for patients (pts) with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) with 17p deletion (del 17p).
Authors
Nimer Alsaid
University of Arizona College of Pharmacy, Tucson, AZ
Nimer Alsaid , Ali McBride , Daniel Oscar Persky , Faiz Anwer , Leslie Ann Andritsos , Abhijeet Kumar , Seongseok Yun , Hani M. Babiker , Ivo Abraham
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7527)
DOI
10.1200/JCO.2018.36.15_suppl.7527
Abstract #
7527
Poster Bd #
164
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib.
First Author: Jeffrey Alan Jones
Poster
2016 ASCO Annual Meeting
Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.
First Author: Jennifer R. Brown
Poster
2023 ASCO Annual Meeting
Two schedules of vincristine, irinotecan and temozolomide (VIT) for patients with relapsed or refractory Ewing sarcoma: A randomized controlled phase 2 trial.
First Author: Jie Xu
Poster
2023 ASCO Annual Meeting
Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
First Author: Katsunori Asai